生長抑素類似物市場 - 全球產業規模、佔有率、趨勢、機會和預測，按類型、按治療、按最終用途、按地區和競爭細分，2020-2030F

2024 年全球生長抑素類似物市場價值為 58.7 億美元，預計到 2030 年將達到 88.9 億美元，預測期內複合年成長率為 7.12%。全球生長抑素類似物市場是製藥和生物技術產業內一個充滿活力且快速發展的產業。生長抑素類似物是合成化合物，旨在模仿人體內天然存在的荷爾蒙生長抑素的作用。這些類似物已廣泛應用於各種醫療狀況的管理，主要與荷爾蒙和神經傳導物質的調節有關。生長抑素類似物市場的發展受到肢端肥大症、神經內分泌腫瘤和類癌症候群等疾病日益流行的推動，這些類似物對於控制過量荷爾蒙分泌和緩解相關症狀至關重要。

全球生長抑素類似物市場的主要促進因素之一是神經內分泌腫瘤 (NET) 發生率的上升，這是一種罕見但診斷率不斷上升的癌症類型。生長抑素類似物是治療 NET 的基石，因為它們有助於控制腫瘤的生長並減輕這些惡性腫瘤常伴隨的衰弱症狀。此外，生長抑素類似物也可用於治療庫欣氏症和與門脈高壓相關的胃腸道出血等疾病，進一步擴大了其市場範圍。

該市場的特點是存在幾家大型製藥公司，這些公司開發和銷售各種生長抑素類似物產品。這些公司投入大量資金進行研發活動，以提高其類似物的功效和安全性，並推動產品創新。此外，產業內的策略合作、夥伴關係和收購正在促進產品組合和地理範圍的擴大。

主要市場促進因素

目標疾病盛行率上升

主要市場挑戰

治療費用高昂

主要市場趨勢

藥物輸送創新

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：顧客之聲

第 5 章：全球生長抑素類似物市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 依類型（奧曲肽、蘭瑞肽、帕瑞肽）
  • 依治療（肢端肥大症、庫欣氏症候群、神經內分泌腫瘤、類癌症候群、其他）
  • 依最終用途（醫院和診所、門診手術中心、其他）
  • 按地區
  • 按公司分類（2024）
• 市場地圖

第 6 章：北美生長抑素類似物市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 加拿大
  • 墨西哥

第 7 章：歐洲生長抑素類似物市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 英國
  • 義大利
  • 法國
  • 西班牙

第 8 章：亞太地區生長抑素類似物市場展望

• 市場規模和預測
• 市場佔有率和預測
• 亞太地區：國家分析
  • 印度
  • 日本
  • 韓國
  • 澳洲

第 9 章：南美洲生長抑素類似物市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 阿根廷
  • 哥倫比亞

第 10 章：中東和非洲生長抑素類似物市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：市場動態

• 驅動程式
• 挑戰

第 12 章：市場趨勢與發展

• 合併與收購（如有）
• 產品發布（如果有）
• 最新動態

第 13 章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 顧客的力量
• 替代產品的威脅

第 14 章：競爭格局

• Bayer AG
• Novartis AG
• Pfizer Inc.
• Sun Pharmaceutical Industries Ltd.
• Midatech Pharma plc
• Crinetics Pharmaceuticals Inc.
• Peptron Inc.
• Teva Pharmaceutical Industries Ltd.
• Camurus AB
• Mylan NV

第 15 章：策略建議

第16章 關於出版商,免責事項

Global Somatostatin Analogs Market was valued at USD 5.87 Billion in 2024 and is expected to reach USD 8.89 Billion by 2030 with a CAGR of 7.12% during the forecast period. The Global Somatostatin Analogs Market is a dynamic and rapidly evolving sector within the pharmaceutical and biotechnology industries. Somatostatin analogs are synthetic compounds designed to mimic the actions of somatostatin, a naturally occurring hormone in the human body. These analogs have found extensive use in the management of various medical conditions, primarily related to the regulation of hormones and neurotransmitters. The market for somatostatin analogs is driven by the increasing prevalence of diseases such as acromegaly, neuroendocrine tumors, and carcinoid syndrome, where these analogs are essential in controlling excessive hormone production and alleviating associated symptoms.

One of the key drivers of the Global Somatostatin Analogs Market is the rising incidence of neuroendocrine tumors (NETs), a rare but increasingly diagnosed cancer type. Somatostatin analogs are a cornerstone in the treatment of NETs, as they help in controlling the growth of tumors and mitigating the debilitating symptoms that often accompany these malignancies. Additionally, somatostatin analogs have also found applications in the management of conditions like Cushing's disease and gastrointestinal bleeding associated with portal hypertension, further expanding their market reach.

The market is characterized by the presence of several major pharmaceutical companies, which have developed and marketed various somatostatin analog products. These companies invest heavily in research and development activities to enhance the efficacy and safety of their analogs, driving product innovation. Moreover, strategic collaborations, partnerships, and acquisitions in the industry are facilitating the expansion of product portfolios and geographical reach.

Key Market Drivers

Rising Prevalence of Targeted Diseases

The rising prevalence of targeted diseases is a significant driving force behind the burgeoning Global Somatostatin Analogs Market. Conditions such as acromegaly, neuroendocrine tumors (NETs), and carcinoid syndrome, which are characterized by excessive hormone production and associated symptoms, have witnessed a notable surge in diagnoses. This upward trend is due to improved disease awareness, early detection methods, and a growing understanding of these conditions within the medical community. According to a study, "Epidemiology, Incidence, and Prevalence of Neuroendocrine Neoplasms: Are There Global Differences?", The overall prevalence of pancreatic NETs (neuroendocrine tumors) was 2.2 cases per 100,000 individuals, with functional tumors occurring at a rate of 1.3 cases per 100,000 and non-functional tumors at 0.95 cases per 100,000. At the time of diagnosis, 21% of pancreatic NETs had already spread to distant sites. For gastrointestinal NETs, the overall prevalence was 3.5 cases per 100,000, with hindgut tumors being the most prevalent. Among gastrointestinal NETs, hindgut, foregut, and midgut tumors accounted for 60%, 30.4%, and 9.6% of cases, respectively. Distant metastasis was noted in 6% of gastrointestinal NETs at presentation. The most common primary sites for these tumors were the rectum, small intestine, and stomach.

One key contributor to the increasing prevalence of these diseases is enhanced screening and diagnostic capabilities. Healthcare providers and medical institutions have become better equipped to identify these hormone-related disorders, leading to earlier intervention and treatment initiation. As a result, patients with conditions like acromegaly and NETs are diagnosed and treated more promptly, spurring the demand for somatostatin analogs.

Furthermore, as the world's population ages, the incidence of diseases associated with hormonal dysregulation, such as acromegaly and certain types of neuroendocrine tumors, is on the rise. These conditions often manifest later in life, and the aging demographic across the globe is contributing to their growing prevalence.

In the case of neuroendocrine tumors, which can affect various organs and have historically been challenging to treat, the use of somatostatin analogs has revolutionized patient care. These compounds effectively control hormone secretion and alleviate debilitating symptoms associated with NETs. As a result, patients are experiencing improved quality of life, and healthcare providers are increasingly incorporating somatostatin analogs into their treatment regimens.

Key Market Challenges

High Treatment Costs

High treatment costs represent a significant obstacle to the growth and accessibility of the Global Somatostatin Analogs Market. Somatostatin analogs, while highly effective in managing conditions such as acromegaly and neuroendocrine tumors, come with a hefty price tag that can be prohibitive for many patients and healthcare systems.

One of the primary reasons for the high treatment costs of somatostatin analogs is the nature of these medications. They are typically administered through injections, often requiring frequent dosing. The cost of manufacturing, packaging, and delivering these injections, along with the need for specialized medical supervision, contributes significantly to the overall treatment expenses. For patients who require long-term therapy, the cumulative costs can become overwhelming.

Additionally, the development and production of somatostatin analogs involve intricate and sophisticated processes. Extensive research and clinical trials are necessary to ensure their safety and efficacy, and these costs are typically passed on to consumers. Furthermore, the limited number of manufacturers and the complexity of the drugs themselves can lead to monopolistic pricing, further exacerbating the financial burden on patients and healthcare systems.

The consequences of high treatment costs are far-reaching. Patients who are unable to afford somatostatin analogs may face delays in treatment initiation or may be forced to discontinue treatment prematurely, potentially compromising their health outcomes. Healthcare providers are also burdened, as they must navigate the challenges of securing funding for these expensive therapies within budget-constrained healthcare systems.

Key Market Trends

Drug Delivery Innovations

Drug delivery innovations are playing a pivotal role in boosting the Global Somatostatin Analogs Market. Traditionally, the administration of somatostatin analogs often involved frequent injections, which could be inconvenient and uncomfortable for patients. However, recent advancements in drug delivery technology have transformed the way these medications are delivered, making treatment more accessible, convenient, and comfortable for patients.

One of the most notable innovations in this regard is the development of long-acting release (LAR) formulations of somatostatin analogs. These formulations extend the duration of action of the drug, allowing for less frequent dosing. Patients may require injections as infrequently as once every few weeks or even once a month, compared to the daily or multiple times daily injections with traditional formulations. This not only simplifies treatment regimens but also improves patient compliance, as the burden of frequent injections is significantly reduced. In September 2021, Amolyt Pharma and PeptiDream Inc. jointly announced that Amolyt Pharma had exercised its option to obtain a global license for a portfolio of macrocyclic peptide growth hormone receptor antagonists (GHRA). The licensed portfolio includes the promising drug candidate, AZP-3813, which is currently undergoing development as a potential treatment for acromegaly. AZP-3813 is intended to complement the use of somatostatin analogs (SSAs), particularly for patients who do not achieve satisfactory responses with SSAs alone.

Key Market Players

• Bayer AG
• Novartis AG
• Pfizer Inc.
• Sun Pharmaceutical Industries Ltd.
• Midatech Pharma plc
• Crinetics Pharmaceuticals Inc.
• Peptron Inc.
• Teva Pharmaceutical Industries Ltd.
• Camurus AB
• Mylan N.V.

Report Scope:

In this report, the Global Somatostatin Analogs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Somatostatin Analogs Market, By Type:

• Octreotide
• Lanreotide
• Pasireotide

Somatostatin Analogs Market, By Treatment:

• Acromegaly
• Cushing's Syndrome
• Neuroendocrine Tumors
• Carcinoid Syndrome
• Others

Somatostatin Analogs Market, By End Use:

• Hospitals &Clinics
• Ambulatory Surgical Centers
• Other

Somatostatin Analogs Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Somatostatin Analogs Market.

Available Customizations:

Global Somatostatin Analogs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Somatostatin Analogs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Octreotide, Lanreotide, Pasireotide)
  • 5.2.2. By Treatment (Acromegaly, Cushing's Syndrome, Neuroendocrine Tumors, Carcinoid Syndrome, Others)
  • 5.2.3. By End Use (Hospitals &Clinics, Ambulatory Surgical Centers, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Somatostatin Analogs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Treatment
  • 6.2.3. By End Use
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Somatostatin Analogs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Treatment
      • 6.3.1.2.3. By End Use
  • 6.3.2. Canada Somatostatin Analogs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Treatment
      • 6.3.2.2.3. By End Use
  • 6.3.3. Mexico Somatostatin Analogs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Treatment
      • 6.3.3.2.3. By End Use

7. Europe Somatostatin Analogs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Treatment
  • 7.2.3. By End Use
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Somatostatin Analogs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Treatment
      • 7.3.1.2.3. By End Use
  • 7.3.2. United Kingdom Somatostatin Analogs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Treatment
      • 7.3.2.2.3. By End Use
  • 7.3.3. Italy Somatostatin Analogs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Treatment
      • 7.3.3.2.3. By End Use
  • 7.3.4. France Somatostatin Analogs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Treatment
      • 7.3.4.2.3. By End Use
  • 7.3.5. Spain Somatostatin Analogs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Treatment
      • 7.3.5.2.3. By End Use

8. Asia-Pacific Somatostatin Analogs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Treatment
  • 8.2.3. By End Use
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Somatostatin Analogs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Treatment
      • 8.3.1.2.3. By End Use
  • 8.3.2. India Somatostatin Analogs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Treatment
      • 8.3.2.2.3. By End Use
  • 8.3.3. Japan Somatostatin Analogs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Treatment
      • 8.3.3.2.3. By End Use
  • 8.3.4. South Korea Somatostatin Analogs Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Treatment
      • 8.3.4.2.3. By End Use
  • 8.3.5. Australia Somatostatin Analogs Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Treatment
      • 8.3.5.2.3. By End Use

9. South America Somatostatin Analogs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Treatment
  • 9.2.3. By End Use
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Somatostatin Analogs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Treatment
      • 9.3.1.2.3. By End Use
  • 9.3.2. Argentina Somatostatin Analogs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Treatment
      • 9.3.2.2.3. By End Use
  • 9.3.3. Colombia Somatostatin Analogs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Treatment
      • 9.3.3.2.3. By End Use

10. Middle East and Africa Somatostatin Analogs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Treatment
  • 10.2.3. By End Use
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Somatostatin Analogs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Treatment
      • 10.3.1.2.3. By End Use
  • 10.3.2. Saudi Arabia Somatostatin Analogs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Treatment
      • 10.3.2.2.3. By End Use
  • 10.3.3. UAE Somatostatin Analogs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Treatment
      • 10.3.3.2.3. By End Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Bayer AG
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Novartis AG
• 14.3. Pfizer Inc.
• 14.4. Sun Pharmaceutical Industries Ltd.
• 14.5. Midatech Pharma plc
• 14.6. Crinetics Pharmaceuticals Inc.
• 14.7. Peptron Inc.
• 14.8. Teva Pharmaceutical Industries Ltd.
• 14.9. Camurus AB
• 14.10. Mylan N.V.

15. Strategic Recommendations

16. About Us & Disclaimer